Growing community of inventors

North Chicago, IL, United States of America

Michelle L Hastings

Average Co-Inventor Count = 1.39

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 22

Michelle L HastingsFrank Rigo (3 patents)Michelle L HastingsOle Isacson (3 patents)Michelle L HastingsJoanna A Korecka-Roet (3 patents)Michelle L HastingsC Frank Bennett (1 patent)Michelle L HastingsMichelle L Hastings (13 patents)Frank RigoFrank Rigo (49 patents)Ole IsacsonOle Isacson (10 patents)Joanna A Korecka-RoetJoanna A Korecka-Roet (3 patents)C Frank BennettC Frank Bennett (201 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Rosalind Franklin University of Medicine and Science (13 from 48 patents)

2. Ionis Pharmaceuticals, Inc. (3 from 270 patents)

3. The Mclean Hospital Corporation (3 from 123 patents)

4. Hastings, Michelle L. (0 patent)


13 patents:

1. 12042508 - Antisense compounds targeting genes associated with cystic fibrosis

2. 11732260 - Compounds and methods for the modulation of amyloid-β precursor protein

3. 11116785 - Antisense compounds targeting genes associated with cystic fibrosis

4. 10787669 - Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons disease

5. 10544417 - Antisense compounds targeting genes associated with cystic fibrosis

6. 10525076 - Antisense compounds targeting genes associated with cystic fibrosis

7. 10472634 - Antisense compounds targeting apolipoprotein E receptor 2

8. 10370667 - Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease

9. 9840709 - Antisense compounds targeting genes associated with cystic fibrosis

10. 9840710 - Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease

11. 9556434 - Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for usher syndrome

12. 9353371 - Antisense compounds targeting genes associated with usher syndrome

13. 8648053 - Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/15/2025
Loading…